Daily obesity pill shows significant weight loss

Trials of a daily obesity pill showed patients lost about 12% of their body weight over 72 weeks.

Daily obesity pill shows promising weight loss results

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over a 72-week period. The drug, named orforglipron, is produced by Eli Lilly. While it is still not licensed, the manufacturer hopes to make it available to the public next year. During the trial, patients taking the highest dose lost an average of 12 kilos, or nearly two stone, over 16 months. However, about one in ten participants stopped taking the pills because of side effects such as nausea and vomiting.

The results from the trials of orforglipron are noteworthy amid the ongoing global obesity crisis. With approximately one in three adults classified as obese, new treatments like this pill could be crucial in addressing this public health issue. However, the reported side effects are concerning, especially considering long-term medication adherence is essential for weight loss success. This is a critical moment for weight management solutions, and the healthcare community is watching closely.

Highlights

Future developments will reveal the long-term impacts of this new treatment.